The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Prospective risks from climate change impacts in ocean and coastal systems are urging the implementation of nature‐based solutions (NBS). These are climate‐resilient strategies to maintain biodiversity and the delivery of ecosystem services, contributing to the adaptation of social‐ecological systems and the mitigation of climate‐related impacts. However, the effectiveness of measures like marine...
Melphalan flufenamide (melflufen) is a novel lipophilic peptide–drug conjugate recently approved in the European Union and the United Kingdom for the treatment of relapsed refractory multiple myeloma. Melflufen rapidly crosses the cell membrane, and inside tumor cells, melflufen utilizes peptidases and esterases to release entrapped hydrophilic metabolites with alkylating activity. In vitro, in whole...
Background
Anal squamous cell carcinoma (ASCC) is an infrequent tumor whose treatment has not changed since the 1970s. The aim of this study is the identification of biomarkers allowing personalized treatments and improvement of therapeutic outcomes.
Methods
Forty‐six paraffin tumor samples from ASCC patients were analyzed by whole‐exome sequencing. Copy number variants (CNVs) were identified and...